ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,222.68
0.16%
US Tech 100
17,650.00
0.05%
Dow Jones
39,512.84
0.32%
Brent Oil
82.585
0.00%
Bitcoin
60,852.20
0.09%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. NeuroSense Therapeutics Ltd (NRSN) Quote

NeuroSense Therapeutics Ltd

NeuroSense Therapeutics Ltd (NRSN)

NASDAQ
1.18
0.0062
(0.53%)
Closed May 11 4:00PM
Delayed by 15 minutes
1.16
-0.02
(-1.69%)
After Hours: 6:09PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
1.16
Bid
1.15
Ask
1.29
Volume
96,731
1.15 Day's Range 1.30
0.40 52 Week Range 2.33
Market Cap
2.122M
Previous Close
1.1738
Open
1.22
Last Trade
1000
@
1.16
(formt)
Last Trade Time
Financial Volume
$ 117,957
VWAP
1.2194
Average Volume (3m)
301,743
Shares Outstanding
11,790,000
Dividend Yield
-
PE Ratio
-0.19
Earnings Per Share (EPS)
-0.96
Revenue
-
Net Profit
-11.28M

About NeuroSense Therapeutics Ltd

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among... NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.neurosense-tx.com
Headquarters
Herzliya, Center, Isr
Founded
1970
NeuroSense Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NRSN. The last closing price for NeuroSense Therapeutics was $1.17. Over the last year, NeuroSense Therapeutics shares have traded in a share price range of $ 0.40 to $ 2.33.

NeuroSense Therapeutics currently has 11,790,000 shares outstanding. The market capitalization of NeuroSense Therapeutics is $2.12 million. NeuroSense Therapeutics has a price to earnings ratio (PE ratio) of -0.19.

NRSN Latest News

More News

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients PR...

May 07 2024
PR Newswire (US)

NeuroSense Announces First Quarter 2024 Business Update

NeuroSense Announces First Quarter 2024 Business Update PR Newswire CAMBRIDGE, Mass., May 2, 2024 CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN...

May 02 2024
PR Newswire (US)

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease PR Newswire CAMBRIDGE, Mass., April 22, 2024 CAMBRIDGE...

April 22 2024
PR Newswire (US)

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting PR Newswire CAMBRIDGE, Mass., April...

April 18 2024
PR Newswire (US)

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 PR Newswire CAMBRIDGE, Mass., April 12, 2024 Emerging Science (Late-Breaker Equivalent...

April 12 2024
PR Newswire (US)

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement PR Newswire CAMBRIDGE, Mass., April 10, 2024 CAMBRIDGE, Mass., April 10, 2024 /PRNewswire/...

April 10 2024
PR Newswire (US)

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics PR Newswire BASEL, Switzerland and CAMBRIDGE...

April 09 2024
PR Newswire (US)

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update PR Newswire CAMBRIDGE, Mass., April 5, 2024 CAMBRIDGE, Mass., April 5, 2024 /PRNewswire/ -- NeuroSense...

April 05 2024
PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

February 22 2024
Edgar (US Regulatory)

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial PR Newswire CAMBRIDGE, Mass., Feb. 21, 2024 PrimeC demonstrated a clinically meaningful effect on quality of...

February 21 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1-7.936507936511.261.491.081605451.27172406CS
4-0.65-35.91160220991.811.811.081271351.37604293CS
12-0.18-13.43283582091.342.331.083017431.6507033CS
260.63118.8679245280.532.330.43135385611.19270481CS
52-0.61-34.46327683621.772.330.43316191.12582902CS
156-3.39-74.50549450554.558.180.411536413.54638332CS
260-3.39-74.50549450554.558.180.411536413.54638332CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LIDRAEye Inc
$ 2.5406
(111.72%)
158.99M
NVAXNovavax Inc
$ 8.90
(98.66%)
170.86M
LGHLWLion Group Holding Ltd
$ 0.0059
(63.89%)
372.41k
ITOSiTeos Therapeutics Inc
$ 17.44
(43.07%)
5.26M
SRTSSensus Healthcare Inc
$ 5.3194
(39.62%)
19.74M
MGNXMacroGenics Inc
$ 3.31
(-77.44%)
35.15M
EVLVEvolv Technologies Holdings Inc
$ 2.355
(-38.67%)
14.74M
GWAVGreenwave Technology Solutions Inc
$ 0.0435
(-37.77%)
91.14M
SGDSafe and Green Development Corporation
$ 0.576
(-32.05%)
6.54M
NBSTWNewbury Street Acquisition Corporation
$ 0.0695
(-30.50%)
10.52k
NVAXNovavax Inc
$ 8.90
(98.66%)
170.86M
LIDRAEye Inc
$ 2.5406
(111.72%)
158.99M
NKLANikola Corporation
$ 0.537
(-6.77%)
113.59M
FFIEFaraday Future Intelligent Electric Inc
$ 0.0458
(12.81%)
101.35M
SQQQProShares UltraPro Short QQQ
$ 10.61
(-0.66%)
99.85M

NRSN Discussion

View Posts
runncoach runncoach 4 days ago
Certainly showing a positive trend on the scientific front.
https://ih.advfn.com/stock-market/NASDAQ/neurosense-therapeutics-NRSN/stock-news/93791685/neurosense-announces-new-positive-data-analysis-fr
👍️0
runncoach runncoach 3 weeks ago
Financing broke the stock for now. Either Biogen news or dead money IMO
👍️0
runncoach runncoach 4 weeks ago
Looks like there will be a data presentation on the sixteenth at a conference. Back in for a gamble at 1.70.
👍️0
runncoach runncoach 1 month ago
And there's the money raise at 1.50
👍️0
runncoach runncoach 1 month ago
Sold at 2.12. Only update today on the additional biomarker data was talking about peer reviews and conferences. I expected data at least a month ago. I'm concerned they'll raise money before we get any significant data updates. I could be making a mistake but taking profits from .79 so can't be too upset if I do. I'll buy back if it goes lower most likely. GLTA
👍️0
glenn1919 glenn1919 2 months ago
NRSN..........................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 months ago
NRSN under $2
👍️0
runncoach runncoach 2 months ago
I like Coya a lot as well. I was hoping to see how the Biogen data plays out here and then moving funds there. Hopefully I'll get that chance. I'm not sure COYA's next coming data will be ideal based on the dosage and other trial parameters but could give a great indication to set up a pivotal P3. Lot of bigger money over there. I've got my eyes on them for sure. JMHO
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
Suggest a look at $COYA for ALS.
👍️0
runncoach runncoach 2 months ago
Disappointed for the ALS community. Hoping NRSN can provide some hope.
https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-topline-results-120000695.html?guccounter=1&guce_referrer=YW5kcm9pZC1hcHA6Ly9jb20uZ29vZ2xlLmFuZHJvaWQuZ29vZ2xlcXVpY2tzZWFyY2hib3gv&guce_referrer_sig=AQAAAAM8h3Ee_7hkwe__ixrWmntWVPdxe8WZ1ZpxVn7ZSc5Y_cvU8dUOeH8gNnkII0GDb_rsadt-ieRtojdTcEbDoBluMPdmwoVEaO7k8HMPi6OgMQhLipitwShkj668qEiwBreTeVNkxishXrsTPgOOOMTmvMybqLk3QVA9AiTxt2Bt
👍️0
runncoach runncoach 2 months ago
If Biogen results are good then yes. If not then no lol. It's a gamble. I'm not buying at these levels but my cost basis is .795 so I don't have to.
👍️0
BurgerKing82 BurgerKing82 2 months ago
Is it good time to buy ?
👍️0
Monksdream Monksdream 2 months ago
NRSN new 52 week high
👍️0
glenn1919 glenn1919 2 months ago
NRSN.................................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
NRSN........................................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783
👍️0
runncoach runncoach 2 months ago
I don't know about the biomarker data or any partnership discussions are going but this sure is a lot of volume in a positive fashion the last couple days.
👍️0
runncoach runncoach 3 months ago
Updated slide presentation fyi
https://ih.advfn.com/stock-market/NASDAQ/neurosense-therapeutics-NRSN/stock-news/93337353/form-6-k-report-of-foreign-issuer-rules-13a-16
👍️0
runncoach runncoach 3 months ago
Looks like additional good news today but the neurofilament results we have been imminently expecting are on track for some time this quarter, which could mean another 5 or 6 weeks. The question remains of how good those results are (or aren't) and if the company raises money before or after. JMHO
👍️0
Awl416 Awl416 3 months ago
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
👍️0
Monksdream Monksdream 3 months ago
NRSN under $2
👍️0
BurgerKing82 BurgerKing82 3 months ago
Tues is the 20th I think....Any day.now?...tick tock....
👍️0
runncoach runncoach 3 months ago
Looks like the neurofilament light data in collaboration with Biogen isn't quite imminent as today's PR says the coming weeks fyi.
👍️0
runncoach runncoach 3 months ago
Looks like the company has regained full Nasdaq compliance
👍️0
BurgerKing82 BurgerKing82 3 months ago
Could be tomorrow lol
👍️0
runncoach runncoach 3 months ago
Not sure the holdup on the neurofilament light data. Though it was supposed to be out in January
👍️0
rouge Vaughn rouge Vaughn 3 months ago
yeah looking forward to 2 dollars and up with volume and news
👍️0
runncoach runncoach 3 months ago
Quite a run today. Fingers crossed on the new data when released
👍️0
runncoach runncoach 3 months ago
Only what you can afford to lose. As risky as any.
👍️0
BurgerKing82 BurgerKing82 3 months ago
How many shares do folks have in here...I was thinking of getting a few
👍️0
BurgerKing82 BurgerKing82 3 months ago
Sounds Rational...In 6/22 it did a little more than 3x on 220 million shares...In December it tripled on much smaller volume...Then again in 6/22 ,I guess it could have went a lot higher in pre- mkt/after-hours,maybe that kinda explains the huge volume....idk seems to have potential for a good rip
👍️0
runncoach runncoach 3 months ago
I don't honestly know. It's seen huge profit taking every time they've put out positive news. Traders/shorters, who knows. The company needs money to advance and when that's the case you see wild swings. The ball is in Biogen's court it would seem. All depends on the biomarker results we should get at any time.
👍️0
BurgerKing82 BurgerKing82 3 months ago
hey Runn....What caused Nrsn to dip.between Dec 4th-6th...just curious
👍️0
BurgerKing82 BurgerKing82 4 months ago
Supposedly they are fully funded into Q2 24'.....As of October 4....There was 22-26 million shares that went buy as the share price declined a bit in December...Maybe it's nothing..."We are optimistic about our mechanisms of action... anticipated in Q4 of 23'".......Still kinda interested


..
👍️0
BurgerKing82 BurgerKing82 4 months ago
This ticker looked pretty attractive until I noticed it was an Israeli one... Similar to Chinese, Israeli ones more often than not....Is it worth setting that factor aside?
👍️0
runncoach runncoach 4 months ago
Potentially yes as long as some of the biomarker data is good. We should find out about that data in the next week or two supposedly to the best of my understanding.
👍️0
BurgerKing82 BurgerKing82 4 months ago
Is there a positive Catalyst Coming later this month?
👍️0
rouge Vaughn rouge Vaughn 5 months ago
you choice is display picture is what is in question, here why are you using that image
👍️0
rakp rakp 5 months ago
Why this sudden reversal?
👍️0
Invest-in-America Invest-in-America 5 months ago
NRSN: How many time must I post this??? READ IT. I quoted the figures ACCURATELY. In any event, this JUNK STOCK is dead!! Let's all MOVE ON!!

https://www.google.com/search?q=is+als+a+rare+disease&sca_esv=588105669&source=hp&ei=an9vZdOZGevHkPIP2rCN8Aw&iflsig=AO6bgOgAAAAAZW-Nem49qIuR5YltejA1r0lBYMi_4ZKE&oq=is+als+a+ra&gs_lp=Egdnd3Mtd2l6IgtpcyBhbHMgYSByYSoCCAAyBRAAGIAEMgYQABgWGB4yCxAAGIAEGIoFGIYDMgsQABiABBiKBRiGA0iRL1AAWJ4YcAB4AJABAJgB0wKgAY4KqgEHNy4yLjEuMbgBAcgBAPgBAcICCxAAGIAEGLEDGIMBwgIOEC4YgAQYsQMYxwEY0QPCAgsQLhiABBjHARjRA8ICBRAuGIAEwgIREC4YgAQYsQMYgwEYxwEY0QPCAggQLhiABBixA8ICCBAAGIAEGLEDwgILEC4YxwEY0QMYgATCAg4QABiABBiKBRixAxiDAcICCxAuGIAEGLEDGIMBwgIXEC4YgAQYsQMYlwUY3AQY3gQY4ATYAQG6BgYIARABGBQ&sclient=gws-wiz
👍️0
runncoach runncoach 5 months ago
You were off somewhere between 30% and 600%. Do you know how much a patient pays a year for ALS medication? That would be quite a bit of difference in sales revenues. Either way potential sales, if ever, are quite a ways off no doubt. If Biogen takes over the indication would likely be much quicker through any approval process. JMHO
👍️0
cintrix cintrix 5 months ago
Do you need validation that bad? YOU stated it was EXTREMELY rare and I noted that I happen to know three people unrelated who got it so how EXTREMELY rare can that be? You want to get into semantics here? If I am a "moron" for stating a personal fact, then you are Infallible with a capital I.
👍️0
Invest-in-America Invest-in-America 5 months ago
WOW!!! I was off by 1/2-of-a-point!!!!!! GOD HELP ME!!!!! (The stolen-Nation of ISRAEL is shit, and so is this FIRM!!)
👍️0
runncoach runncoach 5 months ago
You posted 1-3.
👍️0
Invest-in-America Invest-in-America 5 months ago
Read it and LEARN, you MORONS!!! https://www.google.com/search?q=is+als+a+rare+disease&sca_esv=588067978&source=hp&ei=yVdvZYS2JqbQkPIP_--viAo&iflsig=AO6bgOgAAAAAZW9l2U_dxwvtABn3NZBRnTfqJQKEcJMI&oq=is+als+a+ra&gs_lp=Egdnd3Mtd2l6IgtpcyBhbHMgYSByYSoCCAAyBRAAGIAEMgYQABgWGB4yCxAAGIAEGIoFGIYDMgsQABiABBiKBRiGA0ioLlAAWLwVcAB4AJABAJgBbqABzgeqAQM4LjO4AQHIAQD4AQHCAgsQABiABBixAxiDAcICDhAuGIAEGLEDGMcBGNEDwgILEC4YgAQYxwEY0QPCAgUQLhiABMICERAuGIAEGLEDGIMBGMcBGNEDwgIIEC4YgAQYsQPCAggQABiABBixA8ICDhAAGIAEGIoFGLEDGIMBwgILEC4YgAQYsQMYgwHCAhcQLhiABBixAxiXBRjcBBjeBBjgBNgBAboGBggBEAEYFA&sclient=gws-wiz
👍️0
Invest-in-America Invest-in-America 5 months ago
NRSN: I simply quoted what the NEWS & PR's published.
👍️0
runncoach runncoach 5 months ago
His facts were clearly wrong. Looks like Biogen could determine share price next year. Probably nothing to see here for the next 4-6 weeks imo
👍️0
cintrix cintrix 5 months ago
I don't know if I would call it an extremely RARE disorder since I personally know of three people who got it and none of them were related.
👍️0
Invest-in-America Invest-in-America 5 months ago
Let the PRICE of this determine who is WRONG; and I will leave at that. HAVE A NICE DAY!!
👍️0
runncoach runncoach 5 months ago
It's early in the process. I don't have a dog in the fight at this point but it's the Biogen connection that intrigues me as we await additional biomarker data.
👍️0
FooBarAndGrill FooBarAndGrill 5 months ago
You're not only wrong but you're two orders of magnitude wrong.
👍️0

Your Recent History

NASDAQ
NRSN
NeuroSense Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved